

---

# **CERTIFICATES OF CONFIDENTIALITY**

## **Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff**

### ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 45 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact: Jarilyn Dupont, Office of Policy, 301-796-4850, [Jarilyn.dupont@fda.hhs.gov](mailto:Jarilyn.dupont@fda.hhs.gov).

**U.S. Department of Health and Human Services**

**Food and Drug Administration**

**November 2019**

---

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

# **CERTIFICATES OF CONFIDENTIALITY**

## **Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff**

*Additional copies are available from:*

*Office of Policy*

*Food and Drug Administration*

*10903 New Hampshire Ave., Bldg. 32., Rm. 4239*

*Silver Spring, MD 20993-0002*

*Phone: 301-796-4850 or at*

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents>

**U.S. Department of Health and Human Services  
Food and Drug Administration**

**November 2019**

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

**Table of Contents**

**I. Introduction**

**II. Background**

**III. Scope**

**IV. Request for Discretionary CoC From FDA**

**V. FDA Review and FDA Issuance of Discretionary CoC**

# CERTIFICATES OF CONFIDENTIALITY

## Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

### I. Introduction

This draft guidance<sup>1</sup> describes FDA implementation of the revised provisions applicable to the request for, and issuance of, a Certificate of Confidentiality (CoC). The 21<sup>st</sup> Century Cures Act (Cures Act) (Public Law 114-255) amended the Public Health Service Act (PHS Act), section 301(d) (42 U.S.C. 241(d)) relating to the issuance of CoCs. A CoC is intended to help protect the privacy of human subject research participants from whom identifiable, sensitive information is being collected or used in furtherance of the research.<sup>2</sup> Historically, a CoC generally protected a researcher from being compelled to disclose identifiable and sensitive information about the research participant, created or compiled for purposes of the human subject research. As amended, the statute broadened the protections by affirmatively prohibiting holders of CoCs from disclosing such information unless a specific exception applies.

The Cures Act simplified certain aspects of the issuance of CoCs by requiring that CoCs be issued for federally-funded human subject research that collects or uses identifiable, sensitive information (referred to in this guidance as mandatory CoCs). For non-federally funded research, issuance of CoCs is not required but may be issued at the discretion of FDA (referred to in this guidance as discretionary CoCs). FDA intends to continue receiving and considering such requests and will issue discretionary CoCs as appropriate. This guidance is intended to provide information on how to request a *discretionary* CoC, the statutory requirements for requesting such a CoC, and the statutory responsibilities associated with possessing a CoC. Although the mandatory CoC and the discretionary CoC are issued under different processes, the protections

---

<sup>1</sup> This guidance has been prepared by the Office of Policy in cooperation with the Center for Biologics Evaluation and Research, the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, the Center for Tobacco Products, the Center for Food Safety and Applied Nutrition, the Center for Veterinary Medicine, and the Office of Chief Scientist at the Food and Drug Administration.

<sup>2</sup> There are additional statutes and regulations that protect the privacy of human subject research participants. These are outside the scope of this guidance.

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

afforded by the issuance of either CoC are identical and the statutory responsibilities are the same.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

## **II. Background**

A CoC generally protects a researcher from being compelled to disclose identifiable, sensitive information about the research participant, created or compiled for purposes of the research, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding. As amended, the statute broadened these protections by prohibiting disclosure of such information. There are exceptions to the prohibition on disclosure as detailed in Section III.

FDA has the authority (by delegation) to issue CoCs related to the study of products subject to FDA jurisdiction and to which FDA regulations apply, in compliance with the PHS Act, and has done so for over 20 years. (42 U.S.C. § 241)<sup>3</sup> The Cures Act revisions made issuance of a CoC mandatory for federally funded researchers “engaged in biomedical, behavioral, clinical, or other research, in which identifiable, sensitive information is collected (including research on mental health and research on the use and effect of alcohol and other psychoactive drugs).” For *non-federally funded research*, FDA “*may*, upon application by a person engaged in research, issue to such person a certificate of confidentiality to protect the privacy of such individuals (emphases added) . . . .”

The Cures Act also directed agencies to take steps to minimize the burden to researchers, streamline the process, and reduce the time it takes to comply with the requirements of the statutory provision. FDA has complied with this directive in implementing requirements for the issuance of mandatory CoCs to FDA-federally funded researchers.

For non-federally funded research, FDA has been issuing discretionary CoCs pursuant to the amended statutory requirements, on a case-by-case basis upon application to FDA, since enactment of the Cures Act,. This draft guidance describes the revised, streamlined process for submission to FDA of requests for discretionary CoCs for non-federally funded research. The revised process for discretionary CoCs will minimize the burden to researchers who request a CoC, will streamline the existing process by reducing the information currently provided in a request to FDA for a CoC, will clarify the statutory responsibilities associated with receiving a CoC and, thus, will reduce the time it takes to obtain a CoC.

---

<sup>3</sup> FDA, by delegation from the Secretary, Department of Health and Human Services (HHS), has the authority to issue CoCs . (See, FDA Staff Manual Guide, 1410.26(1)(E)). Other HHS agencies, e.g., National Institutes of Health (NIH), Centers for Disease Control and Prevention, also issue CoCs.

### III. Scope

To help ensure that discretionary CoCs are issued to those entities who can comply with the requirements of the statutory provision, we recommend that only sponsors or sponsor-investigators, submit requests for discretionary CoCs (as defined in 21 CFR §50.3, §312.3, §812.3) (i.e., the individual who takes responsibility for or initiates the clinical investigation). This will help eliminate duplicative requests to FDA for the same human subject research. It is our understanding that, typically, sponsors and sponsor-investigators are the entities or individuals who have responsibility and control over information collected and used in research. Furthermore, the human subject research, for which a discretionary CoC is being requested, must involve the use or study of a product subject to FDA’s jurisdiction and must be subject to FDA’s regulatory authority.

The term “identifiable, sensitive information,” as used in section 301(d), PHS Act, and in relation to CoCs, means “information that is about an individual and that is gathered or used during the course of research” covered by the statute and

(A) through which an individual is identified; or (B) for which there is at least a very small risk, as determined by current scientific practices or statistical methods, that some combination of the information, a request for the information, and other available data sources could be used to deduce the identity of an individual.

(42 U.S.C. § 241(4)). An entity or individual requesting a discretionary CoC should evaluate its own human subject research and make its own determination as to whether the research involves the collection of identifiable, sensitive information (e.g., research participant names). This evaluation should take into account the type of information collected, whether the information is retained for any further use or purpose, the extent of the information, and the security of the data systems that contain the information. In considering whether the individual information being collected is “identifiable, sensitive information,” sponsors, sponsor-investigators, and other researchers should be aware of the evolving perspectives as to the identifiability of the information collected. Given current technological capabilities, there is some support for the position that the identity of an individual participating in certain types of research is relatively easy to determine even with limited de-identified data. Genomic data also are often considered to fall automatically into the category of identifiable, sensitive information.<sup>4</sup>

Once a CoC is issued, the recipient must comply with the statutory disclosure protections as follows (section 301(d)(1), PHS Act):

---

<sup>4</sup> NIH considers research in which identifiable, sensitive information is collected or used, to include “research that involves the generation of individual level, human genomic data from biospecimens, or the use of such data, regardless of whether the data is recorded in such a manner that human subjects can be identified or the identity of the human subjects can readily be ascertained.” (NIH, NOT-OD-17-109: Notice of Changes to NIH Policy for Issuing Certificates of Confidentiality, effective October 1, 2017).

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

- (A) [*defines who can apply and conditions of applying for a CoC*].
- (B) Except as provided in subparagraph (C), any person to whom a certificate is issued . . . to protect the privacy of individuals described in such subparagraph shall not disclose or provide to any other person not connected with the research the name of such an individual or any information, document, or biospecimen that contains identifiable, sensitive information about such an individual and that was created or compiled for purposes of the research.
- (C) The disclosure prohibition in subparagraph (B) shall not apply to disclosure or use that is—
- (i) required by Federal, State, or local laws, excluding instances described in subparagraph (D);
  - (ii) necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the consent of such individual;
  - (iii) made with the consent of the individual to whom the information, document, or biospecimen pertains; or
  - (iv) made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing the protection of human subjects in research.
- (D) Any person to whom a certificate is issued . . . to protect the privacy of an individual described in such subparagraph shall not, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, disclose or provide the name of such individual or any such information, document, or biospecimen that contains identifiable, sensitive information about the individual and that was created or compiled for purposes of the research, except in the circumstance described in subparagraph (C)(iii).
- (E) Identifiable, sensitive information . . . , and all copies thereof, shall be immune from the legal process, and shall not, without the consent of the individual to whom the information pertains, be admissible as evidence or used for any purpose in any action, suit, or other judicial, legislative, or administrative proceeding.
- (F) Identifiable, sensitive information collected by a person to whom a certificate has been issued . . . , and all copies thereof, shall be subject to the protections afforded by this section for perpetuity.
- (G) The Secretary shall take steps to minimize the burden to researchers, streamline the process, and reduce the time it takes to comply with the requirements of this subsection.

As part of the protection of the identifiable, sensitive information collected in the research, any other entities with whom the sponsor, sponsor-investigator, or other researcher shares the information (i.e., “copies” of the information) are also subject to the disclosure requirements. Such entities include contract research organizations, clinical investigators, and academic institutions, among others.

#### **IV. Request for Discretionary CoC From FDA**

Prior to submitting a request to FDA for issuance of a discretionary CoC, the potential requestor should consider the following questions:

- Is the requestor involved in human subject research in which identifiable, sensitive information is collected?

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

- Is the requestor a sponsor or sponsor-investigator or authorized representative (i.e., the individual who takes responsibility for or initiates the clinical investigation)?
- Does the human subject research, for which a discretionary CoC is being requested, involve the use or study of a product subject to FDA’s jurisdiction and subject to FDA’s regulatory authority?
- Are the requestor’s research measures sufficient to protect the confidentiality of the identifiable, sensitive information?<sup>5</sup>

We recommend that a request to FDA for the issuance of a discretionary CoC be made by those entities and individuals that can answer “yes” to all of these questions. A request for a discretionary CoC also should not be made if the human subject research is federally funded.<sup>6</sup> We also prefer that all requests for discretionary CoCs be submitted electronically as described in this section and with the information and assurances as detailed in this section.

To make a request to FDA for a discretionary CoC, the requestor should determine the appropriate Center and submit the request, in the form of a letter (e.g., as a PDF attachment to the email submission), through one of the following email addresses:

Center for Drug Evaluation and Research (CDER) at: [CDER-CoC-Requests@fda.hhs.gov](mailto:CDER-CoC-Requests@fda.hhs.gov)

Center for Biologics Evaluation and Research (CBER) at: [CBERBIMONotification@fda.hhs.gov](mailto:CBERBIMONotification@fda.hhs.gov)

Center for Devices and Radiological Health (CDRH) at: [CDRH-CoC@fda.hhs.gov](mailto:CDRH-CoC@fda.hhs.gov)

Center for Tobacco Products (CTP) at: [CTP\\_RIHSC@fda.hhs.gov](mailto:CTP_RIHSC@fda.hhs.gov)

Center for Food Safety and Applied Nutrition (CFSAN) at: [CFSAN-CoC-Requests@fda.hhs.gov](mailto:CFSAN-CoC-Requests@fda.hhs.gov)

Center for Veterinary Medicine (CVM) at: [AskCVM@fda.hhs.gov](mailto:AskCVM@fda.hhs.gov)

We recommend the request letter include the following information and assurances to facilitate FDA’s review and to expedite consideration of the request for the discretionary CoC.

### ***Descriptive Information***

- Sponsor or Sponsor-Investigator Name or authorized representative (e.g., the individual who takes responsibility for or initiates the clinical investigation).
- Sponsor or Sponsor-Investigator or authorized representative Address (same as on file with FDA).
- Sponsor or Sponsor-Investigator or authorized representative Email Address.

---

<sup>5</sup> The amendments to section 301(d) of the PHS Act, signal Congressional support for enhanced privacy protections for participants in research. FDA recommends that sponsors and investigators explore ways to further enhance their own privacy and confidentiality procedures.

<sup>6</sup> As noted in Section II, CoCs for federally funded research are mandatory and outside the scope of this guidance. Mandatory CoCs for federally funded research are handled in a different manner than discretionary CoCs.



Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

- FDA Application Number, as applicable, (e.g., IND/NDA/BLA/IDE/HDE/PMA/PMTA/ITP)<sup>7</sup>.
- ClinicalTrials.gov Numerical Identifier (if applicable) (number provided upon registration on [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)).
- Research Title
- If conducting human subject research subject to FDA’s jurisdiction but the sponsor or sponsor-investigator is exempt from submission of an investigational application (e.g., IND/IDE) submit all of the above information with the exception of the FDA application number.
- Signature of sponsor, sponsor-investigator, or authorized representative, submitting the discretionary CoC request.

***Assurances***

The requestor should include information sufficient to allow FDA to assess whether the requestor understands its obligations to comply with the CoC statutory provisions (section 301(d), PHS Act, (42 U.S.C. 241(d))). We recommend use of the following language in the request letter to facilitate FDA’s review:

*The requestor is engaged in biomedical, behavioral, clinical, or other research, in which identifiable, sensitive information is collected or used.*

*The requestor agrees it is responsible for complying with requirements to protect the confidentiality of identifiable, sensitive information that is collected or used in biomedical, behavioral, clinical, or other research.*

*The requestor agrees not to disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name of such individual or any such information, document, or biospecimen that contains identifiable, sensitive information about the individual and that was created or compiled for purposes of the research, unless such disclosure or use is made with the consent of the individual to whom the information, document, or biospecimen pertains. The requestor also agrees not to disclose or provide to any other person not connected with the research the name of such an individual or any information, document, or biospecimen that contains identifiable, sensitive information about such an individual and that was created or compiled for purposes of the research.*

*The requestor understands that the identifiable, sensitive information collected by a researcher to whom a discretionary CoC has been issued, and all copies of such information, are subject to the protections afforded by the statute in perpetuity. The requestor understands and agrees that disclosure is permitted by the recipient of a CoC only when:*

---

<sup>7</sup> Investigational New Drug Application/New Drug Application/Biologics License Application/Investigational Device Exemption/Humanitarian Device Exemption/Premarket Application/Premarket Tobacco Product Application/Investigational Tobacco Product.

Contains Nonbinding Recommendations  
*Draft – Not for Implementation*

- *Required by Federal, State, or local laws (e.g., as required by the Federal Food, Drug, and Cosmetic Act, or state laws requiring the reporting of communicable diseases to State and local health departments), excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding;*
- *Necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the consent of such individual;*
- *Made with the consent of the individual to whom the information, document, or biospecimen pertains; or*
- *Made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing the protection of human subjects in research.*

*The requestor also should note that the signature provided for this request, if a facsimile or e-signature, represents a true and correct signature of the sponsor, sponsor-investigator, or that of an authorized representative, authorized to submit this request for a Certificate of Confidentiality and to make these assurances.*

## **V. FDA Review and FDA Issuance of Discretionary CoC**

After a request has been sent to the appropriate Center responsible for the FDA-regulated product, a review will be conducted to ensure the requestor has submitted all the information and assurances, described in Section IV. After FDA completes its review, the Center will send an electronic response letter to the requestor indicating whether or not the discretionary CoC has been granted. If granted, that electronic response letter will serve as the CoC. The recipient of the CoC is expected to carry out the statutory assurances provided in the request and reiterated in the FDA electronic response letter for the protection of the individuals participating in the human subject research.